New Immune-Guiding drug takes on stubborn arthritis
NCT ID NCT06946199
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called cizutamig in 28 people with severe rheumatoid arthritis that hasn't responded to other treatments. The drug works by directing the immune system to attack certain cells involved in the disease. The main goal is to check safety, but researchers will also look for signs that the drug might help control arthritis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cizutamig (a drug that directs immune cells to attack certain cells involved in rheumatoid arthritis)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat rheumatoid arthritis.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The drug may cause side effects or fail to improve arthritis symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••